The Effect of Oral Polymeric Diet Enriched With TGF-beta 2 (Modulen) on Clinical Response and Mucosal Healing in Adult Patients With Newly Diagnosed Crohn's Disease

NCT ID: NCT04233463

Last Updated: 2020-01-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-31

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate prospectively a possible effect of an oral polymeric diet enriched with TGF-beta 2 (Modulen) as compared to Budesonide (one of the commonly accepted treatments for Crohn's disease) on clinical response, mucosal healing and intestinal microbiota in adult patients with newly diagnosed Crohn's disease using a capsule endoscopy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Modulen Diet

Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet

Group Type ACTIVE_COMPARATOR

Modulen

Intervention Type DIETARY_SUPPLEMENT

Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet

Budesonide Treatment

Crohn patients will be given Budesonide treatment

Group Type ACTIVE_COMPARATOR

Budesonide

Intervention Type DRUG

Standard treatment for mild Crohn Disease patients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Modulen

Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet

Intervention Type DIETARY_SUPPLEMENT

Budesonide

Standard treatment for mild Crohn Disease patients

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly diagnosed Crohn's Disease
* Mild to moderate severity

Exclusion Criteria

* Patients who received systemic steroid or Budesonide or biological treatment
* Recent bowel surgery
* Colostomy, ileostomy
* Short bowel syndrome
* Obstructive symptoms
* Pregnancy, lactation
* Cardiac pacemaker or defibrillator
* Swallowing problems
* Uncontrolled metabolic diseases or any other condition that can be exacerbated by steroids
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hillel Yaffe Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Baruch Ovadia, MD

Role: PRINCIPAL_INVESTIGATOR

Hillel Yaffe Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hillel Yaffe Medical Center

Hadera, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Baruch Ovadia, MD

Role: CONTACT

972-545767372

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Baruch Ovadia, MD

Role: primary

972-545767372

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0128-18-HYMC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MSC Intratissular Injection in Crohn Disease Patients
NCT03901235 RECRUITING PHASE1/PHASE2
Low Dose IL-2 for the Treatment of Crohn's Disease
NCT04263831 RECRUITING PHASE1/PHASE2
Dietary Treatment of Crohn's Disease
NCT00343642 COMPLETED PHASE1/PHASE2